scispace - formally typeset
P

Peter J. Barnes

Researcher at National Institutes of Health

Publications -  1554
Citations -  177909

Peter J. Barnes is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 194, co-authored 1530 publications receiving 166618 citations. Previous affiliations of Peter J. Barnes include University of Nebraska Medical Center & Novartis.

Papers
More filters
Journal ArticleDOI

Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite–sensitive patients with asthma

TL;DR: House dust mite-sensitive DCs exposed to Der p 1 downregulated IDO activity and tipped the T(H)1/T( H)2 cytokine balance toward IL-4, resulting in sustainable IDO suppression.
Journal ArticleDOI

Sputum plasminogen activator inhibitor-1 elevation by oxidative stress-dependent nuclear factor-κB activation in COPD.

TL;DR: It is shown that PAI-1 elevation in COPD is closely associated with oxidative stress-induced nuclear factor κB (NF-κB) activation, and Oxidative stress, directly or indirectly via HDAC reduction, plays a role in PAi-1 expression in COPd via activation of NF- κ B.
Journal ArticleDOI

Differential expression of IL‐10 receptor by epithelial cells and alveolar macrophages

TL;DR: This data indicates that suppression of IL‐10 secretion from alveolar macrophages in patients with asthma may result in exaggerated and more prolonged inflammatory responses in asthmatic airways.
Journal Article

Diagnosis of asthma and chronic obstructive pulmonary disease in general practice.

TL;DR: A pragmatic, primary care definition of asthma and chronic obstructive pulmonary disease is put forward, which relies on objective parameters, such as determining the presence and degree of reversibility of airway obstruction, diurnal peak flow variability, bronchial hyper-responsiveness and allergy.
Journal ArticleDOI

Extracellular Adenosine 5'-Triphosphate in Obstructive Airway Diseases

TL;DR: The purpose of this review was to describe these studies and outline some of the remaining questions, as well as the potential clinical implications, associated with the pharmacologic manipulation of ATP signaling in the lungs.